GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Illumina Inc (XTER:ILU) » Definitions » Cyclically Adjusted PB Ratio

Illumina (XTER:ILU) Cyclically Adjusted PB Ratio : 3.01 (As of Jun. 04, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Illumina Cyclically Adjusted PB Ratio?

As of today (2024-06-04), Illumina's current share price is €94.69. Illumina's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €31.46. Illumina's Cyclically Adjusted PB Ratio for today is 3.01.

The historical rank and industry rank for Illumina's Cyclically Adjusted PB Ratio or its related term are showing as below:

XTER:ILU' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.93   Med: 19.32   Max: 31.26
Current: 3.07

During the past years, Illumina's highest Cyclically Adjusted PB Ratio was 31.26. The lowest was 2.93. And the median was 19.32.

XTER:ILU's Cyclically Adjusted PB Ratio is ranked worse than
68.18% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 1.955 vs XTER:ILU: 3.07

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Illumina's adjusted book value per share data for the three months ended in Mar. 2024 was €33.178. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €31.46 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Illumina Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Illumina's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Illumina Cyclically Adjusted PB Ratio Chart

Illumina Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.33 20.63 16.31 6.94 4.27

Illumina Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.67 5.98 4.27 4.27 4.08

Competitive Comparison of Illumina's Cyclically Adjusted PB Ratio

For the Diagnostics & Research subindustry, Illumina's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Illumina's Cyclically Adjusted PB Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Illumina's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Illumina's Cyclically Adjusted PB Ratio falls into.



Illumina Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Illumina's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=94.69/31.46
=3.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Illumina's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Illumina's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=33.178/131.7762*131.7762
=33.178

Current CPI (Mar. 2024) = 131.7762.

Illumina Quarterly Data

Book Value per Share CPI Adj_Book
201406 5.704 100.560 7.475
201409 6.964 100.428 9.138
201412 8.260 99.070 10.987
201503 10.414 99.621 13.775
201506 11.046 100.684 14.457
201509 11.786 100.392 15.471
201512 11.577 99.792 15.287
201603 12.157 100.470 15.945
201606 12.480 101.688 16.173
201609 13.587 101.861 17.577
201612 14.246 101.863 18.430
201703 16.336 102.862 20.928
201706 16.550 103.349 21.102
201709 16.406 104.136 20.761
201712 15.802 104.011 20.020
201803 16.624 105.290 20.806
201806 18.966 106.317 23.508
201809 20.422 106.507 25.267
201812 22.471 105.998 27.936
201903 23.991 107.251 29.477
201906 25.904 108.070 31.586
201909 27.419 108.329 33.354
201912 28.243 108.420 34.327
202003 28.571 108.902 34.572
202006 27.753 108.767 33.624
202009 27.331 109.815 32.797
202012 26.428 109.897 31.690
202103 28.322 111.754 33.396
202106 29.248 114.631 33.622
202109 57.351 115.734 65.300
202112 60.541 117.630 67.822
202203 62.975 121.301 68.413
202206 62.930 125.017 66.332
202209 43.301 125.227 45.566
202212 39.427 125.222 41.491
202303 39.565 127.348 40.941
202306 38.293 128.729 39.200
202309 34.801 129.860 35.315
202312 33.133 129.419 33.736
202403 33.178 131.776 33.178

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Illumina  (XTER:ILU) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Illumina Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Illumina's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Illumina (XTER:ILU) Business Description

Traded in Other Exchanges
Address
5200 Illumina Way, San Diego, CA, USA, 92122
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates about 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (about 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Illumina (XTER:ILU) Headlines

No Headlines